Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis
ObjectiveCannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and relaps...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.824051/full |
| _version_ | 1819178297739706368 |
|---|---|
| author | Priyanthi B. Gjerde Priyanthi B. Gjerde Priyanthi B. Gjerde Synne W. Steen Synne W. Steen Trude S. J. Vedal Trude S. J. Vedal Nils Eiel Steen Nils Eiel Steen Elina J. Reponen Ole A. Andreassen Ole A. Andreassen Vidar M. Steen Vidar M. Steen Ingrid Melle Ingrid Melle |
| author_facet | Priyanthi B. Gjerde Priyanthi B. Gjerde Priyanthi B. Gjerde Synne W. Steen Synne W. Steen Trude S. J. Vedal Trude S. J. Vedal Nils Eiel Steen Nils Eiel Steen Elina J. Reponen Ole A. Andreassen Ole A. Andreassen Vidar M. Steen Vidar M. Steen Ingrid Melle Ingrid Melle |
| author_sort | Priyanthi B. Gjerde |
| collection | DOAJ |
| description | ObjectiveCannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and relapse in patients with first treatment for psychosis (FTP). However, to date, it is unclear whether cannabis use may be related to negative perceptions about antipsychotic drug treatment.MethodsA cross-sectional sample of 265 FTP patients with schizophrenia spectrum disorder underwent extensive clinical assessments. Three measures of cannabis use were obtained: lifetime, current and meeting diagnostic criteria for abuse or addiction. For the primary analyses we focused on lifetime cannabis use. The Beliefs about Medication Questionnaire (BMQ) was employed to assess the patients' specific concerns and perceptions of antipsychotic medications, as well as general beliefs about pharmacotherapy. The relationship between lifetime cannabis use and BMQ scores was investigated with general linear model (GLM) analyses, controlling for age and sex.ResultsPatients with lifetime use of cannabis ≥10 times were more likely to be male, younger at the age of onset of psychosis and with higher levels of alcohol use and daily tobacco smoking, as compared to the non-users (p < 0.05). Neither lifetime use of cannabis, current use nor a cannabis abuse diagnosis was associated with negative beliefs about medicines as measured by the BMQ questionnaire.ConclusionUse of cannabis is not linked to negative perceptions about antipsychotic medicines in patients with FTP. Other reasons for poor compliance to antipsychotic drug treatment in cannabis users need to be further investigated. |
| first_indexed | 2024-12-22T21:40:19Z |
| format | Article |
| id | doaj.art-e6fbb68054e54dafa34b41fa9cefa17f |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-22T21:40:19Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-e6fbb68054e54dafa34b41fa9cefa17f2022-12-21T18:11:38ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402022-03-011310.3389/fpsyt.2022.824051824051Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment PsychosisPriyanthi B. Gjerde0Priyanthi B. Gjerde1Priyanthi B. Gjerde2Synne W. Steen3Synne W. Steen4Trude S. J. Vedal5Trude S. J. Vedal6Nils Eiel Steen7Nils Eiel Steen8Elina J. Reponen9Ole A. Andreassen10Ole A. Andreassen11Vidar M. Steen12Vidar M. Steen13Ingrid Melle14Ingrid Melle15Norwegian Centre for Mental Disorders Research, Department of Clinical Science, University of Bergen, Bergen, NorwayDr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, NorwayResearch Unit for General Practice, NORCE Norwegian Research Centre, Bergen, NorwayNorwegian Centre for Mental Disorders Research, Department of Clinical Science, University of Bergen, Bergen, NorwayDr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, NorwayDivision of Mental Health, Akershus University Hospital, Oslo, NorwayNORMENT, Oslo University Hospital, Oslo, NorwayNORMENT, Oslo University Hospital, Oslo, NorwayInstitute of Clinical Medicine, University of Oslo, Oslo, NorwayNORMENT, Oslo University Hospital, Oslo, NorwayNORMENT, Oslo University Hospital, Oslo, NorwayInstitute of Clinical Medicine, University of Oslo, Oslo, NorwayNorwegian Centre for Mental Disorders Research, Department of Clinical Science, University of Bergen, Bergen, NorwayDr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, NorwayNORMENT, Oslo University Hospital, Oslo, NorwayInstitute of Clinical Medicine, University of Oslo, Oslo, NorwayObjectiveCannabis use is common among patients with psychosis, and along with negative beliefs about medication, it has been found to predict poor adherence to antipsychotic drug treatment. Such lack of adherence to antipsychotic drug treatment increases the risk of poor clinical outcomes and relapse in patients with first treatment for psychosis (FTP). However, to date, it is unclear whether cannabis use may be related to negative perceptions about antipsychotic drug treatment.MethodsA cross-sectional sample of 265 FTP patients with schizophrenia spectrum disorder underwent extensive clinical assessments. Three measures of cannabis use were obtained: lifetime, current and meeting diagnostic criteria for abuse or addiction. For the primary analyses we focused on lifetime cannabis use. The Beliefs about Medication Questionnaire (BMQ) was employed to assess the patients' specific concerns and perceptions of antipsychotic medications, as well as general beliefs about pharmacotherapy. The relationship between lifetime cannabis use and BMQ scores was investigated with general linear model (GLM) analyses, controlling for age and sex.ResultsPatients with lifetime use of cannabis ≥10 times were more likely to be male, younger at the age of onset of psychosis and with higher levels of alcohol use and daily tobacco smoking, as compared to the non-users (p < 0.05). Neither lifetime use of cannabis, current use nor a cannabis abuse diagnosis was associated with negative beliefs about medicines as measured by the BMQ questionnaire.ConclusionUse of cannabis is not linked to negative perceptions about antipsychotic medicines in patients with FTP. Other reasons for poor compliance to antipsychotic drug treatment in cannabis users need to be further investigated.https://www.frontiersin.org/articles/10.3389/fpsyt.2022.824051/fullpsychosisschizophreniacannabissubstance abuseBMQ |
| spellingShingle | Priyanthi B. Gjerde Priyanthi B. Gjerde Priyanthi B. Gjerde Synne W. Steen Synne W. Steen Trude S. J. Vedal Trude S. J. Vedal Nils Eiel Steen Nils Eiel Steen Elina J. Reponen Ole A. Andreassen Ole A. Andreassen Vidar M. Steen Vidar M. Steen Ingrid Melle Ingrid Melle Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis Frontiers in Psychiatry psychosis schizophrenia cannabis substance abuse BMQ |
| title | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
| title_full | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
| title_fullStr | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
| title_full_unstemmed | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
| title_short | Lifetime Cannabis Use Is Not Associated With Negative Beliefs About Medication in Patients With First Treatment Psychosis |
| title_sort | lifetime cannabis use is not associated with negative beliefs about medication in patients with first treatment psychosis |
| topic | psychosis schizophrenia cannabis substance abuse BMQ |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2022.824051/full |
| work_keys_str_mv | AT priyanthibgjerde lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT priyanthibgjerde lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT priyanthibgjerde lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT synnewsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT synnewsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT trudesjvedal lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT trudesjvedal lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT nilseielsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT nilseielsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT elinajreponen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT oleaandreassen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT oleaandreassen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT vidarmsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT vidarmsteen lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT ingridmelle lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis AT ingridmelle lifetimecannabisuseisnotassociatedwithnegativebeliefsaboutmedicationinpatientswithfirsttreatmentpsychosis |